FCCC LOGO Faculty Publications
Murphy Maureen
Sequences of murine protein Map4 gene promoter and human survivin gene promoter, and methods for p53-mediated repression of gene expression
. 2001 20001002. :84 pp
PMID: AN 2001:247457   
Back to previous list
Abstract
Compns. and methods are provided for identifying novel therapeutic agents for the treatment of cancer and other cellular proliferative disorders. The invention provides sequences of murine protein Map4 gene promoter and human survivin gene promoter contg. p53 neg. response elements. In a aspect of the invention a process for producing a host cell contg. a heterologous gene operably linked to the survivin or Map4 promoter is provided. Addnl., the promoter sequence utilized may be the native promoter sequence or one or more of the minimal p53 repress or elements. Methods utilizing the expression constructs and host cells contg. the same for identifying agents which affect the promoter activity of the Map4 or survivin gene are also provided in the present invention. In a further aspect of the invention, methods are provided for screening the Map4 and survivin promoter for mutations assocd. with pathol. conditions. Another aspect of the invention provides a method for selectively targeting p53 dysfunctional tumor cells for destruction, while sparing normal cells. The method comprises administering to a patient a DNA construct comprising the aforementioned DNA segment operably linked to a coding sequence which, upon expression, produces a product that renders the cell a target for destruction by an exogenous agent. [on SciFinder (R)]
Notes
CAN 134:275751 1-6 Pharmacology Patent written in English. 20010405 9002-06-6 (Thymidine kinase) Role: BSU (Biological study, unclassified), BIOL (Biological study) (from simplex virus, HSV-TK, gene for; sequences of murine protein Map4 gene promoter and human survivin gene promoter, and methods for p53-mediated repression of gene expression); 9001-78-9 (Alkaline phosphatase); 9014-00-0 (Luciferase); 9040-07-7 (Chloramphenicol acetyltransferase) Role: BSU (Biological study, unclassified), BIOL (Biological study) (gene for, as reporter; sequences of murine protein Map4 gene promoter and human survivin gene promoter, and methods for p53-mediated repression of gene expression); 332191-12-5; 332191-13-6 Role: BOC (Biological occurrence), BPR (Biological process), BSU (Biological study, unclassified), PRP (Properties), THU (Therapeutic use), BIOL (Biological study), OCCU (Occurrence), PROC (Process), USES (Uses) (nucleotide sequence; sequences of murine protein Map4 gene promoter and human survivin gene promoter, and methods for p53-mediated repression of gene expression); 332345-96-7 Role: PRP (Properties) (nucleotide sequence; sequences of murine protein Map4 gene promoter and human survivin gene promoter, and methods for p53-mediated repression of gene expression); 82410-32-0 (Gancyclovir) Role: BPR (Biological process), BSU (Biological study, unclassified), THU (Therapeutic use), BIOL (Biological study), PROC (Process), USES (Uses) (sequences of murine protein Map4 gene promoter and human survivin gene promoter, and methods for p53-mediated repression of gene expression); 332191-16-9; 332191-17-0; 332191-18-1; 332191-19-2; 332191-20-5; 332191-21-6; 332192-13-9; 332192-14-0 Role: PRP (Properties) (unclaimed nucleotide sequence; sequences of murine protein Map4 gene promoter and human survivin gene promoter, and methods for p53-mediated repression of gene expression) A2 US 99-157171 19990930